DYAI Dyadic International, Inc.
Listings ·
Nasdaq started a process that could lead to delisting after Dyadic missed the June 17, 2026 deadline to meet the $1.00 minimum bid price. The company plans to request a hearing, and the request automatically stays any delisting action until the panel decides.
Dyadic received a Nasdaq notice on March 27, 2026 that it is out of compliance with Listing Rule 5550(b). It has until May 11, 2026 to submit a plan to regain compliance, and a separate bid price deadline of June 17, 2026 also stands.
Gross proceeds would be $5,749,400. The price compares with a last reported sale of $1.1750 on July 29, 2025. An executive agreed to buy 26,000 shares.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $3.1 million | $3.5 million |
| Research and development | $2.2 million | $2.0 million |
| Net income (loss) | -$7.4 million | -$5.8 million |
| Cash from operations | -$5.7 million | -$4.0 million |
| Cash and equivalents | $4.6 million | $6.5 million |
| Short-term investments | $2.7 million | $2.8 million |
Our latest story on this, dated Jun 18, 2026: "Dyadic International gets Nasdaq delisting notice over bid price, plans hearing". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 30, 2025: "Dyadic International prices 6,052,000-share offering at $0.95, below last trade". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 30, 2026: "Dyadic International gets Nasdaq deficiency notice under Rule 5550(b) minimum listing requirements". The story links the filing or release it is based on. Read the story.
Dyadic International, Inc. trades under the ticker DYAI on NASDAQ.
Dyadic International, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Dyadic International, Inc. is 1213809. Its filings are on SEC EDGAR.
36,438,703 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Dyadic International, Inc. under United States.
Our directory classifies Dyadic International, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Dyadic International, Inc. is US26745T1016.
aibio.space lists Dyadic International, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$3.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Dyadic International, Inc. reported a net loss of $7.4 million for the fiscal year ended Dec 31, 2025, and used $5.7 million of cash in operations, per its annual report to the SEC.
$2.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio